Hormonal
Bypassing or modifying the small intestine (via surgery or endoscopy) induces type 2 diabetes remission and improves glycemic control, independent of weight loss alone.
If you have obesity and Type 2 Diabetes, standard weight loss might not be enough. Modern endoscopic procedures that target the small intestine (like bypass liners or mucosal resurfacing) can induce diabetes remission and improve blood sugar control, often with less risk than traditional surgery. However, these are complex treatments requiring a multidisciplinary team to select the right procedure for your specific body type and ethnicity.
We have learned from metabolic surgery that those procedures that bypass large portions of the small intestine not only have excellent weight reduction but also induce type 2 diabetes (T2D) remission and improve glycemic control, both in the short term and the long term.
Why this rating
This is an editorial summarizing various studies (surgery, endoscopy, drugs) rather than a single primary clinical trial.
Source
Small intestine is a big player!
Ivo Boškoski · Digestive Endoscopy · 2023
DOI 10.1111/den.14624
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →